表紙
市場調査レポート

ウェゲナー肉芽腫症:パイプライン製品の分析

Wegener's Granulomatosis - Pipeline Review, H1 2015

発行 Global Markets Direct 商品コード 302489
出版日 ページ情報 英文 45 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.69円で換算しております。
Back to Top
ウェゲナー肉芽腫症:パイプライン製品の分析 Wegener's Granulomatosis - Pipeline Review, H1 2015
出版日: 2015年05月13日 ページ情報: 英文 45 Pages
概要

ウェゲナー肉芽腫症とは血管の炎症を引き起こす難病の一種で、血管の炎症により様々な人体組織への血流が妨げられるという特徴があります。主な症状・徴候として、持続的な鼻水や鼻血、耳感染症、咳、胸痛、皮膚の爛れ、発熱などが挙げられます。また、年齢などが主な疾病素質に含まれています。主な治療法として、免疫抑制治療やコルチコステロイド剤などがあります。

当レポートでは、世界各国でのウェゲナー肉芽腫症治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などを調査して、その結果を概略以下の構成でお届けします。

目次

イントロダクション

  • 分析範囲

ウェゲナー肉芽腫症の概要

治療薬の開発

  • ウェゲナー肉芽腫症向けパイプライン製品:概要
  • ウェゲナー肉芽腫症向けパイプライン製品:比較分析

各企業で開発中のウェゲナー肉芽腫症治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

ウェゲナー肉芽腫症治療薬:開発中の製品の一覧(企業別)

ウェゲナー肉芽腫症治療薬の開発に従事している企業

  • Amgen Inc.
  • Celltrion, Inc.
  • 日本化薬
  • Panacea Biotec Limited
  • Anthera Pharmaceuticals, Inc.
  • Biosidus S.A.
  • Aprogen, Inc.
  • Curaxys, S.L.
  • Epirus Biopharmaceuticals, Inc.

ウェゲナー肉芽腫症:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 機能メカニズム別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • gusperimus trihydrochloride
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • blisibimod
  • リツキシマブのバイオシミラー(その1〜その8)

ウェゲナー肉芽腫症治療薬:パイプライン製品の最新動向

ウェゲナー肉芽腫症治療薬:開発が休止状態の製品

ウェゲナー肉芽腫症治療薬:開発が中止された製品

ウェゲナー肉芽腫症関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース(全5件)

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC6760IDB

Summary

Global Markets Direct's, 'Wegener's Granulomatosis - Pipeline Review, H1 2015', provides an overview of the Wegener's Granulomatosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Wegener's Granulomatosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wegener's Granulomatosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Wegener's Granulomatosis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Wegener's Granulomatosis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Wegener's Granulomatosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Wegener's Granulomatosis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Wegener's Granulomatosis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Wegener's Granulomatosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Wegener's Granulomatosis Overview
  • Therapeutics Development
    • Pipeline Products for Wegener's Granulomatosis - Overview
    • Pipeline Products for Wegener's Granulomatosis - Comparative Analysis
  • Wegener's Granulomatosis - Therapeutics under Development by Companies
  • Wegener's Granulomatosis - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Wegener's Granulomatosis - Products under Development by Companies
  • Wegener's Granulomatosis - Companies Involved in Therapeutics Development
    • Aprogen, Inc.
    • ChemoCentryx, Inc.
    • Epirus Biopharmaceuticals, Inc.
    • Hospira, Inc.
    • Panacea Biotec Limited
    • Sandoz International GmbH
    • Therapeutic Proteins International, LLC
  • Wegener's Granulomatosis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • CCX-168 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rituximab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rituximab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rituximab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rituximab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rituximab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rituximab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rituximab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Wegener's Granulomatosis - Recent Pipeline Updates
  • Wegener's Granulomatosis - Dormant Projects
  • Wegener's Granulomatosis - Discontinued Products
  • Wegener's Granulomatosis - Product Development Milestones
    • Featured News & Press Releases
      • Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Wegener's Granulomatosis, H1 2015
  • Number of Products under Development for Wegener's Granulomatosis - Comparative Analysis, H1 2015
  • Number of Products under Development by Companies, H1 2015
  • Comparative Analysis by Clinical Stage Development, H1 2015
  • Comparative Analysis by Early Stage Development, H1 2015
  • Products under Development by Companies, H1 2015
  • Wegener's Granulomatosis - Pipeline by Aprogen, Inc., H1 2015
  • Wegener's Granulomatosis - Pipeline by ChemoCentryx, Inc., H1 2015
  • Wegener's Granulomatosis - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2015
  • Wegener's Granulomatosis - Pipeline by Hospira, Inc., H1 2015
  • Wegener's Granulomatosis - Pipeline by Panacea Biotec Limited, H1 2015
  • Wegener's Granulomatosis - Pipeline by Sandoz International GmbH, H1 2015
  • Wegener's Granulomatosis - Pipeline by Therapeutic Proteins International, LLC, H1 2015
  • Assessment by Monotherapy Products, H1 2015
  • Number of Products by Stage and Target, H1 2015
  • Number of Products by Stage and Mechanism of Action, H1 2015
  • Number of Products by Stage and Route of Administration, H1 2015
  • Number of Products by Stage and Molecule Type, H1 2015
  • Wegener's Granulomatosis Therapeutics - Recent Pipeline Updates, H1 2015
  • Wegener's Granulomatosis - Dormant Projects, H1 2015
  • Wegener's Granulomatosis - Discontinued Products, H1 2015

List of Figures

  • Number of Products under Development for Wegener's Granulomatosis, H1 2015
  • Number of Products under Development for Wegener's Granulomatosis - Comparative Analysis, H1 2015
  • Number of Products under Development by Companies, H1 2015
  • Comparative Analysis by Clinical Stage Development, H1 2015
  • Assessment by Monotherapy Products, H1 2015
  • Number of Products by Top 10 Targets, H1 2015
  • Number of Products by Stage and Top 10 Targets, H1 2015
  • Number of Products by Top 10 Mechanism of Actions, H1 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
  • Number of Products by Top 10 Routes of Administration, H1 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2015
  • Number of Products by Top 10 Molecule Types, H1 2015
  • Number of Products by Stage and Top 10 Molecule Types, H1 2015
Back to Top